Clinical Trials Directory

We are doing this study to find out if images taken of the eye using a special type of camera placed inside a surgical microscope, called Microscope Integrated Optical Coherence Tomography (MIOCT), will give us new information during surgery that will improve both how we perform eye surgery and the results of surgery.

We are doing this study to find the most effective, safe dose of an experimental drug called INT230-6 (the study drug) in people with recurrent, inoperable, or metastatic soft tissue sarcomas (STS). We also want to know how well it works compared to the usual treatments for people with this diagnosis.

We are using this registry to learn more about acute aortic dissection from hospitals across the country.

We are doing this study to learn more about prostate cancer and whether certain treatments are related with different outcomes and patient experiences.

This study begins with a screening period that lasts about 28 days to see if a person can join. If eligible, participants will receive a study medicine called JANX014. This is a new immune based drug that is given through a vein at a clinic or hospital. The medicine may be given once every week, every two weeks, or every three weeks, depending on the study group and safety results. The study has two parts. In the first part, small groups receive different dose levels to find a safe amount of the medicine. In the second part, more people receive selected doses to learn more about safety and early effects. During the study, participants will have regular visits that include physical exams, blood and urine tests, heart tests, and imaging scans such as CT or PET scans. Some early treatment visits may require short hospital stays so doctors can watch closely. Participants may also check their temperature and blood pressure at home.